Chinese investment firms Hillhouse Capital and Quan Capital have invested US$93 million in a series B equity financing round in bio-pharmaceutical company NextCure Inc., which mainly focuses on developing immunomedicines for cancers and other diseases, according to an announcement released by NextCure. Investors, including Ping An Ventures, the venture capital vehicle of China’s largest insurer […]
Hillhouse, Quan Capital Lead $93M Series B Round In Biopharma Firm NextCure appeared first on China Money Network.